A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

Key Points

• Inhibition of hepatitis B virus entry occurs through interference with sodium taurocholate co-transporting polypeptide oligomerization.
• The synthetic bile acid derivative shows potential for therapeutic development against hepatitis B infection.
• Assessment using a novel synthetic derivative targets viral entry mechanisms at a cellular level.
• Further investigation is necessary to validate efficacy in clinical settings, as findings are based on laboratory studies.